23andMe Holding Co. - Common Stock (ME)

Frequently Asked Questions About 23andMe Holding Co. - Common Stock (ME)

Can 23andMe results impact healthcare decisions?

Yes, the results from 23andMe can provide valuable information that may influence healthcare decisions. For instance, individuals may learn about their predisposition to certain health conditions and can make proactive lifestyle choices or consult with healthcare providers about genetic risks.

Has 23andMe expanded internationally?

Yes, 23andMe has expanded its services internationally beyond the United States. The company offers its genetic testing services in several countries, allowing a wider audience to access personalized genetic insights and enhancing the global understanding of genetics and health.

How does 23andMe contribute to research?

23andMe contributes to research by compiling vast databases of genetic information that can be used in studies related to health and disease. The company's unique consumer-genetics model enables researchers to gain insights that may lead to breakthroughs in understanding complex health conditions.

How does 23andMe protect customer privacy?

23andMe takes customer privacy seriously and implements strict measures to ensure the security of personal data. Customers have control over their genetic information and can choose whether to share their results for research purposes. The company adheres to stringent data protection regulations to safeguard personal information.

How does the 23andMe genetic testing process work?

The genetic testing process with 23andMe begins with customers purchasing a DNA test kit online. After receiving the kit, they collect a saliva sample and send it back to the company for analysis. Once the analysis is complete, customers receive their health and ancestry reports online.

How has the market performed for 23andMe stock?

Since going public, the performance of 23andMe stock has experienced fluctuations characteristic of the biotech sector. Various factors, including financial results, product launches, and market trends, can significantly affect the stock's valuation, making it important for investors to stay informed about company developments.

Is 23andMe FDA approved?

Yes, 23andMe has received approval from the U.S. Food and Drug Administration (FDA) for several of its genetic tests. The company was the first to receive FDA approval for direct-to-consumer genetic testing, ensuring that the health reports provided are reliable and based on scientific evidence.

What are some of the ethical considerations around genetic testing by 23andMe?

The ethical considerations surrounding genetic testing with 23andMe include concerns about genetic privacy, potential discrimination based on genetic information, and the complexities of informed consent. The company prioritizes transparency and provides customers with information on how their data may be used, emphasizing the importance of user choice.

What are the costs associated with 23andMe services?

The cost of 23andMe tests varies depending on the type of service. Generally, the ancestry-only service is less expensive, while the health and ancestry service is priced higher due to the additional information provided. Pricing often reflects the company's ongoing innovations and the comprehensive nature of their reports.

What does 23andMe do?

23andMe is a biotechnology company that focuses on personal genomics and biotechnology. The company provides genetic testing services that allow individuals to explore their ancestry, genetic traits, health predispositions, and carrier status for various genetic conditions through DNA analysis.

What future plans does 23andMe have?

Moving forward, 23andMe aims to continue enhancing its genetic testing offerings while expanding its research capabilities. The company is also focusing on developing new partnerships within the pharmaceutical industry to accelerate drug discovery and improve personalized medicine, as well as exploring additional markets for its services.

What is 23andMe's mission statement?

23andMe's mission is to help people access, understand, and benefit from the human genome. By empowering individuals with genetic information, the company aims to improve health and increase awareness about genetic science, ultimately transforming healthcare through personalized genetics.

What is the 23andMe research program?

The 23andMe research program allows customers to participate in genetic research that can lead to insights into health and disease. By consenting to have their genetic data anonymously used in research, participants contribute to advancing scientific understanding and the development of new therapies.

What is the company's stock symbol and exchange?

23andMe is publicly traded under the stock symbol 'ME' on the Nasdaq stock exchange. The company went public through a merger with a special purpose acquisition company (SPAC) in June 2021, allowing it to raise capital and enhance its business operations.

What is the significance of the name '23andMe'?

The name '23andMe' refers to the 23 pairs of chromosomes that make up the human genome, combined with 'me' to emphasize personal genetics. This name encapsulates the company’s mission to provide individuals with insights about their own genetic background.

What partnerships has 23andMe formed?

23andMe has formed various partnerships, particularly in the biotechnology and pharmaceuticals sectors. The company collaborates with researchers and biotech firms to leverage genetic data for drug discovery and development, helping to personalize medicine and improve health outcomes.

What types of reports does 23andMe provide?

23andMe provides a variety of reports including Ancestry Reports, Health Reports, and Trait Reports. Ancestry Reports detail genetic heritage and lineage, Health Reports offer insights into genetic health risks and carrier status for certain conditions, while Trait Reports reveal information about unique traits such as eye color and taste preferences.

When was 23andMe founded?

23andMe was founded in 2006 by Anne Wojcicki, Linda Avey, and Paul Cusenza. The company aimed to empower individuals through direct access to their genetic information and to catalyze a new model of healthcare focused on personalized medicine.

What is the current price of 23andMe Holding Co. - Common Stock?

The current price of 23andMe Holding Co. - Common Stock is 0.6063

When was 23andMe Holding Co. - Common Stock last traded?

The last trade of 23andMe Holding Co. - Common Stock was at 4:00 pm EDT on March 28th, 2025